Stocks
UCB S.A.UCBJY
OTCHealthcareBiotechnology$143.36-1.17%
Price as of · delayed, not real-time
A global biopharmaceutical company focused on developing treatments for severe diseases in neurology and immunology, UCB S.A. is known for its innovative pipeline and established products like Cimzia and Vimpat. Investors monitor its R&D progress and regulatory milestones given its specialization in niche therapeutic areas with high unmet needs.
Market Cap: $54.6B52W Range: $71.16 – $168.76
Congressional Interest in UCB S.A. (UCBJY)
2 members of Congress have disclosed 3 trades in UCB S.A. (UCBJY), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
1
Sells
2
Who in Congress Is Trading UCBJY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-09-23 | Valerie Hoyle | sell | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-02-27 | Daniel Goldman | buy | $1K – $15K |